相关实验视频
Updated: Jun 25, 2025

09:53
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
7.4K
miRNA-21是自身免疫性疾病的重要调节者
Roghayeh Tofigh1, Reza Safaralizadeh1, Mohammadali Hosseinpourfeizi1
1Department of Animal Biology, Faculty of Natural Sciences, University of Tabriz, Tabriz, Iran.
Current molecular medicine
|May 28, 2024
概括
微RNA-21 (miRNA-21) 是细胞中的关键调节剂,与多发性硬化症和狼等自身免疫性疾病的发展有关. 这项研究调查了其在自身免疫性疾病中的致病作用.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 微RNA-21 (miRNA-21) 是丰富且保存的,在细胞功能中发挥关键的调节作用.
- miRNA-21涉及各种免疫相关和自身免疫性疾病的发病.
- 诸如多发性硬化症和系统性红斑狼等自身免疫性疾病是miRNA-21可能起作用的例子.
研究的目的:
- 研究miRNA-21在自身免疫性疾病的发展中的特定作用.
- 了解miRNA-21在自身免疫性疾病的背景下的病原性意义.
主要方法:
- 这项研究的重点是分析miRNA-21的作用.
- 研究了miRNA-21作为自身免疫性疾病发展的致病因子.
主要成果:
- miRNA-21被确定为一个显著的致病性微RNA.
- 这项研究强调了miRNA-21在自身免疫性疾病的进展中的作用.
结论:
- miRNA-21在自身免疫性疾病的发病过程中起着至关重要的作用.
- 对miRNA-21的机制的进一步研究可能会导致对自身免疫性疾病的新治疗策略.
相关概念视频
Autoimmune Disorders
417
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
417
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
158
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
158
siRNA - Small Interfering RNAs
16.7K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131

